From the Journals

Long-acting injectable antiretroviral combo as good as HIV oral therapy


 

FROM THE LANCET

A long-acting injectable formulation combining two antiretroviral drugs – cabotegravir and rilpivirine – is as effective as a daily oral regimen of cabotegravir plus abacavir and lamivudine, according to interim results from the LATTE-2 trial.

Writing in the July 24 online edition of The Lancet, researchers have reported the 96-week results of the ongoing open-label phase 2b trial involving 286 treatment-naive adults infected with HIV-1.

Dr. David A. Margolis

Dr. David A. Margolis

After a 20-week induction on daily oral cabotegravir plus abacavir–lamivudine, participants were randomized either to intramuscular long-acting cabotegravir plus rilpivirine at 4-week or 8-week intervals, or to continue with the oral therapy.

At 32 weeks, 95% of patients in 8-week group, 94% of patients in the 4-week group, and 91% of patients in the oral therapy group had maintained viral suppression, defined as plasma HIV-1 RNA less than 50 copies per mL (Lancet. 2017 Jul 24. doi: 10.1016/S0140-6736[17]31917-7).

By week 96, viral suppression was seen in 94% of patients in the 8-week group, 87% of patients in the 4-week group and 84% of patients on oral treatment.

A nonresponse at 96 weeks was seen in five patients in the 8-week group and one patient in the oral therapy group. There were also two patients in the 8-week group and one in the oral treatment group who met the criteria for virologic failure.

“Viral genotyping analysis for the patient in the oral treatment group had no treatment-emergent resistance mutations in the genes encoding viral reverse transcriptase, protease, or integrase,” wrote David A. Margolis, MD, from ViiV Healthcare, and his coauthors.

Injection-site pain was the most common adverse event in the injectable groups, experienced by 96%-97% of patients, but most reactions were mild or moderate and lasted a median of 3 days.

There was only one drug-related serious adverse event, which was a migraine that occurred in one patient during the oral induction period. None of the other serious adverse events were deemed to be drug-related.

Patients reported high levels of treatment satisfaction across all study groups, and more than 99% of patients in the injectable treatment arms said they would be highly satisfied to continue with the regimen, compared with 78% of patients in the oral treatment arm.

“The acceptability and tolerability of injectable dosing options will be an important component of long-term treatment success, and a high degree of treatment satisfaction will avail this option for patients burdened by life-long daily oral medication compliance,” the authors wrote.

However they did note that the study population was mostly white men with a CD4+ cell count at entry of at least 200 cells per mm.

“Therefore, the efficacy, safety, and pharmacokinetic outcomes of long-acting cabotegravir plus rilpivirine in different subpopulations infected with HIV-1 needs further evaluation,” the investigators concluded.

The study was funded by ViiV Healthcare and Janssen R&D. Nine authors are employees of ViiV Healthcare and shareholders in GlaxoSmithKline. Nine authors declared funding, grants, and honoraria from a range of pharmaceutical companies including ViiV Healthcare. Two authors are employees and shareholders of GlaxoSmithKline. Two authors are employees of Janssen, and stockholders of Johnson & Johnson, AstraZeneca, or GlaxoSmithKline. One author had no conflicts to disclose.

Recommended Reading

FDA approves generic version of HIV drug Truvada
MDedge Infectious Disease
All isn’t well with HIV-exposed uninfected infants
MDedge Infectious Disease
Measles immunization is a major challenge in HIV-infected children
MDedge Infectious Disease
HCV/HIV-coinfected teens rapidly progress to advanced liver disease
MDedge Infectious Disease
HIV-positive patients with metabolic syndrome have high rate of hand OA
MDedge Infectious Disease
U.S. goals for earlier HIV diagnosis and treatment may be out of reach
MDedge Infectious Disease
Start ART in first 3 months in infants with perinatal HIV
MDedge Infectious Disease
Children with HIV benefit from double dose of PCV13 vaccine
MDedge Infectious Disease
Subsequent squamous cell carcinoma risk higher in HIV patients with low CD4 count
MDedge Infectious Disease
Enhanced antimicrobial prophylaxis cuts advanced HIV mortality
MDedge Infectious Disease